drugset / Trial / NCT03829891

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

NCT03829891

Completed 60 enrolled Xijing Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators aimed to assess the efficacy and safety of Beinaglutide versus glargine , in individuals with type 2 diabetes who did not achieve adequate glycaemic control with oral antidiabetic drug.

Timeline

Start
2018-08-07
Primary completion
2019-12-31
Completion
2020-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Beinaglutide Protein / enzyme biologic
Subject insulin glargine Protein / enzyme biologic